
His latest order identifies more than 45 categories for zero import tariffs from “aligned partners” who clinch framework pacts to…
With increasing government policy support, innovation, and digitalisation, many Indian businesses are growing at a fast pace. Here are three…
India’s $3 bn contract research, development and manufacturing (CRDMO) sector is set to grow at 18% CAGR till FY30, says…
Allowing data exclusivity would prevent the drug regulator — Central Drugs Standard Control Organisation — from granting marketing approval for…
India’s July exports rose 7.3% to $37.24 bn on strong US sales, but imports surged, widening the trade deficit to…
Nomura’s June 2025 analysis shows Indian pharma majors like Sun Pharma, Dr. Reddy’s, Cipla, Lupin, and Zydus posting strong specialty…
Tarun Mathur, CTO of Indegene, on how pharma firms can responsibly scale GenAI, the guardrails needed for compliance, and emerging…
Elara Capital observes that Aurobindo Pharma has 14 biosimilars in the pipeline. The company has also filed 3 biosimilars for…
The US has imposed a steep 25 per cent tariff on Indian goods, targeting key export sectors like textiles, diamonds,…
Sun Pharma slides 6% after weak Q1 FY26 results, but Motilal Oswal still recommends Buy—discover the three reasons to consider…
The White House has extended key tariff exemptions under Executive Order 14257, shielding sectors like copper, steel, pharmaceuticals, and auto…
Trump’s new tariffs spark uncertainty for India’s pharma exports and stocks; check out how the sector is reacting and what…
Markets today at open, July 31: Markets plunge after Trump’s 25% tariff on Indian imports; track key losers and gainers…
US President Donald Trump has announced a 25 per cent tariff and secondary sanctions on Indian goods starting August 1.…
Jubilant Pharmova reported a 78.66 per cent decline in Q1 profit due to a high base effect, even as revenue…
As Q1FY26 earnings season heats up, Swiggy, Mahindra & Mahindra, ITC, Tata Power, Sun Pharma, UPL, and Maruti Suzuki are…
Dr Gaurav Kharya of Indraprastha Apollo Hospitals explains how stem cell therapies could potentially cure severe Type 1 diabetes. Explore…
Cipla reports 10 per cent rise in net profit to Rs 1,298 crore for Q1FY26 with India business crossing Rs…